It has been reported that tumour‐released HSP90 and HSP70 trigger muscle atrophy through activation of TLR4 [37], and HSP90 inhibitors can effectively alleviate skeletal muscle consumption caused by CC [38], indicating HSP90 may be the potential therapeutic target for attenuating CC. The gene discussed is TLR4; the disease is neoplasm.